References
- ↑ SAMJ. Medical Association of South Africa. 1970. pp. 449–450.
Diffuse hypertrophy of the breasts seems to have been associated in this patient with treatment with Neothetazone, which consists of neotizide and thiacetazone, and which is very commonly used in the treatment of tuberculosis.
- 1 2 Sakai Y, Wakamatsu S, Ono K, Kumagai N (2002). "Gigantomastia induced by bucillamine". Annals of Plastic Surgery. 49 (2): 193–5. doi:10.1097/00000637-200208000-00013. PMID 12187348.
Drug-induced mammary hyperplasias have been reported as rare complications of D-penicillamine and Neothetazone. [...] It is rare for breast hypertrophy to be induced by drugs. In particular, gigantomastia has been reported to be induced by only two drugs: D-penicillamine and the antibiotic neothetazone. [...] In 1970, drug-induced gigantomastia was reported for the first time by Scott.4 It was induced by the antibiotic Neothetazone.
- 1 2 Dancey A, Khan M, Dawson J, Peart F (2008). "Gigantomastia--a classification and review of the literature". Journal of Plastic, Reconstructive & Aesthetic Surgery. 61 (5): 493–502. doi:10.1016/j.bjps.2007.10.041. PMID 18054304.
- ↑ Lynch MJ, Butler CE (2004). "Congenital and Acquired Disorders of Breast Development and Growth". In Singletary SE, Robb GL, Hortobagyi GN (eds.). Advanced Therapy of Breast Disease. PMPH-USA. pp. 20–. ISBN 978-1-55009-262-2.
- ↑ Lima M (27 September 2013). Pediatric Thoracic Surgery. Springer Science & Business Media. pp. 316–. ISBN 978-88-470-5202-4.
 | This systemic antibiotic-related article is a stub. You can help Wikipedia by adding missing information. |